JP Morgan Chase
TEVA icon

JP Morgan Chase’s Teva Pharmaceuticals TEVA Stock Holding History

JP Morgan Chase’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Hold
50,000
– – ﹤0.01% 4357
2025
Q4 		$1.56M Buy
50,000
+6,800
+16% +$168K ﹤0.01% 4286
2025
Q3 		$873K Buy
+43,200
New +$759K ﹤0.01% 4688
2025
Q1 		– Sell
-19,600
Closed -$432K – 7724
2024
Q4 		$432K Sell
19,600
-655,400
-97% -$11.9M ﹤0.01% 5120
2024
Q3 		$12.2M Buy
+675,000
New +$11.8M ﹤0.01% 2436
2024
Q1 		– Sell
-400,000
Closed -$4.18M – 7876
2023
Q4 		$4.18M Buy
+400,000
New +$3.73M ﹤0.01% 3250
2022
Q1 		– Sell
-87,100
Closed -$698K – 7012
2021
Q4 		$698K Sell
87,100
-825,000
-90% -$7.45M ﹤0.01% 4628
2021
Q3 		$8.88M Buy
912,100
+150,000
+20% +$1.4M ﹤0.01% 2488
2021
Q2 		$7.54M Buy
762,100
+539,500
+242% +$5.71M ﹤0.01% 2680
2021
Q1 		$2.57M Sell
222,600
-3,136,900
-93% -$36M ﹤0.01% 3509
2020
Q4 		$32.4M Buy
3,359,500
+222,600
+7% +$2.13M ﹤0.01% 1299
2020
Q3 		$27.8M Buy
3,136,900
+260,000
+9% +$2.75M ﹤0.01% 1286
2020
Q2 		$35.5M Buy
2,876,900
+571,900
+25% +$6.47M 0.01% 1034
2020
Q1 		$20.7M Sell
2,305,000
-1,383,200
-38% -$14.2M ﹤0.01% 1234
2019
Q4 		$36.1M Buy
3,688,200
+111,800
+3% +$998K 0.01% 1155
2019
Q3 		$24.6M Buy
3,576,400
+2,119,000
+145% +$16.2M ﹤0.01% 1440
2019
Q2 		$13.2M Buy
+1,457,400
New +$17.6M ﹤0.01% 1879
2019
Q1 		– Sell
-295,000
Closed -$4.55M – 6041
2018
Q4 		$4.55M Buy
295,000
+199,100
+208% +$4.08M ﹤0.01% 2649
2018
Q3 		$2.06M Buy
95,900
+900
+0.9% +$20.9K ﹤0.01% 3447
2018
Q2 		$2.31M Sell
95,000
-100,700
-51% -$2.05M ﹤0.01% 3308
2018
Q1 		$3.35M Buy
195,700
+700
+0.4% +$13.7K ﹤0.01% 2904
2017
Q4 		$3.69M Buy
195,000
+125,000
+179% +$1.88M ﹤0.01% 2918
2017
Q3 		$1.2M Hold
70,000
– – ﹤0.01% 3420
2017
Q2 		$2.33M Sell
70,000
-61,500
-47% -$1.9M ﹤0.01% 2946
2017
Q1 		$4.22M Buy
131,500
+125,000
+1,923% +$4.27M ﹤0.01% 2552
2016
Q4 		$236K Buy
+6,500
New +$260K ﹤0.01% 4104
2016
Q3 		– Sell
-2,007,400
Closed -$101M – 4795
2016
Q2 		$101M Buy
+2,007,400
New +$107M 0.03% 562
2016
Q1 		– Sell
-200,000
Closed -$13.1M – 4934
2015
Q4 		$13.1M Hold
200,000
– – ﹤0.01% 1627
2015
Q3 		$11.3M Sell
200,000
-105,000
-34% -$6.81M ﹤0.01% 1664
2015
Q2 		$18M Buy
305,000
+45,000
+17% +$2.78M ﹤0.01% 1472
2015
Q1 		$16.2M Buy
260,000
+83,700
+47% +$4.87M ﹤0.01% 1584
2014
Q4 		$10.1M Buy
+176,300
New +$9.82M ﹤0.01% 1936
2014
Q1 		– Sell
-22,000
Closed -$882K – 3919
2013
Q4 		$882K Hold
22,000
– – ﹤0.01% 3208
2013
Q3 		$831K Sell
22,000
-5,800
-21% -$226K ﹤0.01% 3374
2013
Q2 		$1.09M Buy
+27,800
New +$1.08M ﹤0.01% 3206

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's TEVA Position: Q1 2026 in Review

JP Morgan Chase increased its Teva Pharmaceuticals (TEVA) stake by 466% in Q1 2026, buying an estimated $179M and bringing the position to 6,762,744 shares worth $192M. The position accounts for 0.01% of the portfolio, ranked #712.

JP Morgan Chase first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $492M in Q3 2016. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • JP Morgan Chase held 6,762,744 shares of Teva Pharmaceuticals worth $192M as of Q1 2026.
  • JP Morgan Chase bought 5,568,294 Teva Pharmaceuticals shares in Q1 2026, an estimated $179M.
  • Teva Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #712 holding.
  • JP Morgan Chase first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Teva Pharmaceuticals position peaked at $492M in Q3 2016.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.